StocksMediumUpdated•Originally published 5 November 2026•Updated 5 November 2026•
1 min read
Novavax Raises 2026 Revenue Guidance to $400 Million Following Q3 Results
Key Facts
1Novavax reported total revenue of $68 million for the third quarter of 2026.
2The company raised its full-year 2026 total revenue guidance by $145 million to a midpoint of $400 million.
3Novavax earned a $125 million milestone payment following Sanofi's launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
Novavax reported total revenue of $68 million for the third quarter of 2026, according to a statement released via PR Newswire. The company raised its full-year 2026 total revenue guidance by $145 million to a midpoint of $400 million.
The company earned a $125 million milestone payment following Sanofi's launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. NVAX closed at $10.65 on November 4, 2026, while Sanofi shares under the ticker SNY closed at $47.47 on the same date.
Latest Updates · 1
- Notable·
Update: Financial results showed Novavax posted a loss of $0.19 per share for the third quarter of 2026. This performance exceeded analyst estimates, which had projected a wider loss of $0.34 per share.